LQDA — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-12

• Cost of product sales includes direct and indirect costs related to the manufacturing of inventory products sold, including third-party manufacturing costs, packaging services, freight, storage costs, allocation of overhead costs of employees involved with manufacturing and net sales-based royalty e…

• Product sales, net, were $300.3 million for the six months ended June 30, 2026, compared to $6.5 million for the six months ended June 30, 2025. We began shipping YUTREPIA to our customers in the United States in June 2025, following receipt of full FDA approval for YUTREPIA on May 23, 2025. The inc…

• Service revenue, net, was $1.3 million for the three months ended June 30, 2026, compared to $2.3 million for the three months ended June 30, 2025. Service revenue, net was related primarily to the Promotion Agreement. The decrease of $1.0 million was primarily due to the impact of unfavorable gross…

• Service revenue, net, was $4.3 million for the six months ended June 30, 2026, compared to $5.4 million for the six months ended June 30, 2025. Service revenue, net was related primarily to the Promotion Agreement. The decrease of $1.1 million was primarily due to the impact of unfavorable gross-to-…

• Cost of product sales was $10.8 million for the three months ended June 30, 2026, compared to $0.2 million for the three months ended June 30, 2025. Cost of products sales is related to sales of YUTREPIA. The increase of $10.6 million was primarily due to higher volume of YUTREPIA sales.

Text removed vs the prior filing · source: 10-Q · 2026-05-11

• subcutaneous administration of Treprostinil Injection will continue to be constrained. Revenue will continue to be impacted unless and until alternative pumps are available.

• Cost of product sales includes direct and indirect costs related to the manufacturing of inventory products sold, including third-party manufacturing costs, packaging services, freight, storage costs, allocation of overhead costs of employees involved with manufacturing and net sales-based royalty e…

• Service revenue, net, was $3.0 million for the three months ended March 31, 2026, compared to $3.1 million for the three months ended March 31, 2025. Service revenue, net was related primarily to the Promotion Agreement. The decrease of $0.1 million was primarily due to the impact of unfavorable gro…

• Cost of product sales was $11.1 million for the three months ended March 31, 2026. Cost of products sales is related to sales of YUTREPIA. We did not record any cost of product sales during the three months ended March 31, 2025.

• Cost of service revenue was $0.8 million for the three months ended March 31, 2026, compared to $1.5 million for the three months ended March 31, 2025. The decrease from 2025 to 2026 reflects a lower allocation of the cost of our commercial field force to Treprostinil Injection resulting from the co…

Text added vs the prior filing · source: 10-Q · 2026-08-12

• This indebtedness may create additional financing risk for us, particularly if our business or prevailing financial market conditions are not conducive to paying off or refinancing our outstanding debt obligations at maturity. This indebtedness could also have important negative consequences, includ…

• ●increasing our vulnerability to adverse economic and industry conditions;

• ●limiting our ability to obtain additional financing on acceptable terms;

• ●requiring the dedication of a substantial portion of our cash flow from operations to service debt, reducing cash available for other purposes;

• ●limiting our flexibility to plan for, or react to, changes in our business; and

Text removed vs the prior filing · source: 10-Q · 2026-05-11

• For example, beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenditures in the year incurred and instead requires taxpayers to capitalize and subsequently amortize

• such expenditures over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. The One Big Beautiful Bill Act (“OBBBA”) reinstates the option to deduct domestic research and development expenditures in the year …

• ever, the number of patients that can receive subcutaneous administration of Treprostinil Injection will continue to be constrained, which would continue to adversely affect sales of Treprostinil Injection.

• If we are found to infringe, misappropriate or otherwise violate any of United Therapeutics’ intellectual property rights, we could be required to obtain a license from United Therapeutics to continue developing and marketing YUTREPIA. However, we may not be able to obtain any required license on co…

• currently developing or that we may develop. Our competitors may also succeed in asserting existing patents or developing new patents, including patents that may issue from patent applications that are currently being pursued by United Therapeutics, to which we do not have a license, in an attempt t…